In Israel, Evogene has announced its Q3 results, with revenues increasing to $4M, an 18% improvement over Q3 of 2011 due in part to last year’s collaboration with Monsanto. Evogene’s president and CEO, Ofer Haviv, indicated that the company will focus on four divisions in the coming year: yield and abiotic stress, biotic stress, ag-chemicals, and biofuel. R&D spending increased from $4.6M in 2011 to $5.2M, and Evogene attributes the higher expenses to research for the expansion of the biofuel program.
Related Articles
- US and Israel to cooperate on biofuels research
- Evogene considers trading on U.S. markets
- Evogene Announces Launch of Gene2Product Computational AgBio Platform
- Evogene's biojet fuel mets key international standards
- Evogene lifts revenues, demonstrates castor-based jet fuel
- Evogene, SLC Agricola expand Brazilian castor bean partnership
- Evogene releases castor bean lifecycle assessment: 90 percent GHG reduction compared to petroleum diesel
- Evogene launches Evofuel next-gen feedstock venture
- New $100M fund for Israeli water, energy, smart ag ventures
- Monsanto buys activities of Israel’s Rosetta Green for $35M
- UniVerve Biofuel reaches Israeli competition finals with algae technology
- Codexis, Dupont, Shell, Danisco, Novozymes, Monsanto and Syngenta added to Biofuels Digest stock index
- US-Israeli BIRD program awards $8.1M in grants, Covanta a winner
- USDA deregulates Monsanto’s drought-tolerant trait for corn
- Tel Aviv University begins growing salt cedar trees that are Sahara-friendly
Tags: evogene, Israel, Monsanto
Category: International
Comments (0)
Trackback URL | Comments RSS Feed
There are no comments yet. Why not be the first to speak your mind.